Burns Matteson Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Burns Matteson Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-7,009	Closed	-$291K	–	165
2024 Q2	$291K	Buy	+7,009	New	+$314K	0.18%	115
2023 Q4	–	Sell	-9,500	Closed	-$551K	–	139
2023 Q3	$551K	Buy	+9,500	New	+$582K	0.35%	80
2023 Q2	–	Sell	-8,089	Closed	-$561K	–	145
2023 Q1	$561K	Sell	8,089 -634	-7%	-$44.7K	0.36%	76
2022 Q4	$628K	Buy	+8,723	New	+$658K	0.42%	69
2022 Q3	–	Sell	-11,278	Closed	-$868K	–	125
2022 Q2	$868K	Buy	+11,278	New	+$859K	0.61%	28

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Burns Matteson Capital Management's BMY Position: Q3 2024 in Review

Burns Matteson Capital Management sold out of Bristol-Myers Squibb (BMY) in Q3 2024, closing a stake of 7,009 shares — an estimated $291K sold.

Burns Matteson Capital Management first reported a position in BMY in Q2 2022 and held it in 5 quarters. The position peaked at $868K in Q2 2022. 2,259 funds tracked by Wall St. Rank hold BMY as of Q3 2024.

Burns Matteson Capital Management reported no remaining Bristol-Myers Squibb position as of Q3 2024 after selling out during the quarter.
Burns Matteson Capital Management sold 7,009 Bristol-Myers Squibb shares in Q3 2024, an estimated $291K.
Burns Matteson Capital Management first reported a position in Bristol-Myers Squibb in Q2 2022 and held it in 5 quarters.
Burns Matteson Capital Management's Bristol-Myers Squibb position peaked at $868K in Q2 2022.
2,259 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2024.

Based on Burns Matteson Capital Management's 13F filing for Q3 2024, filed 10 Oct 2024.